Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP
Mandate

VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP

October 05, 2015

Vinge and Latham & Watkins LLP have advised Hellman & Friedman in connection with the acquisition of Bain Capital’s stake in Securitas Direct Verisure Group. Verisure Securitas Direct is a leading supplier of professionally monitored home alarms, fire alarms and connected services for homes and businesses. The company’s 1.8 million customers are spread over 13 countries in Europe and South America. The transaction is subject to customary regulatory conditions and approvals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Linda Sengul and Carl Sander. Partner Louise Brorsson Salomon and associates Anders Morén and Linn Adelwald provided financing advice in relation to the transaction.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026